Quality of care for secondary prevention for patients with coronary heart disease: Results of the Hastening the Effective Application of Research through Technology (HEART) trial

American Heart Journal

Volumn 146, Issue 6, 2003, Pages 1045-1051

  Goff Jr , David C ^a   Gu, Lin ^a   Cantley, Larry K ^a,b   Sheedy, David J ^c   Cohen, Stuart J ^d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b PARTNERS Natl Hlth Plans NC Inc   (United States)

^c Solem Health Solutions   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; FEMALE; HEALTH CARE QUALITY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION;

EID: 0344758976     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00522-2     Document Type: Article

References (35)

1. American Heart Association. 2002 heart and stroke statistical update. Dallas, Tex; 2001.
2. Pearson TA, Rapaport E, Criqui M, et al. Optimal risk factor management in the patient after coronary revascularization. Circulation 1994;90:3125-33.
3. Pearson TA, McBride PE, Miller NH, Smith SC Jr. Task Force 8. Organization of preventive cardiology service. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary heart disease. JACC 1996;27:1030-47.
4. Smith SC, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. Circulation 1995;92:2-4.
5. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 2001;104: 1577-9.
6. Thomas RJ, Miller NH, Lamendola C, et al. National survey on gender differences in cardiac rehabilitation programs: patient characteristics and enrollment patterns. J Cardiopulm Rehabil 1996;16:402-12.
7. Vogel RA. Risk factor intervention and coronary artery disease: clinical strategies. Coron Artery Dis 1995;6:466-71.
8. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999;14:711-7.
9. Fonarow GC, French WJ, Parsons LS, et al. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction - data from the National Registry of Myocardial Infarction 3. Circulation 2001;103:38-44.
10. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83:1303-7.
11. Massing MW, Sueta CA, Chowdhury M, Biggs DP, Simpson RJ Jr. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol 2001;87:646-9.
12. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998;280:623-9.
13. Dall L, Simmons T, Peterson S, Herndon B. Beta-blocker use in patients with acute myocardial infarction treated by hospitalists. Managed Care Interface 2000;13:61-3, 69.
14. Fehrenbach SN, Budnitz DS, Gazmararian JA, Krumholz HM. Physician characteristics and the initiation of beta-adrenergic blocking agent therapy after acute myocardial infarction in a managed care population. Am J Managed Care 2001;7:717-23.
15. Dwamena FC, El-Tamimi H, Watson RE, et al. The use of angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction in community hospitals. Michigan State University Inter-Institutional Collaborative Heart (MICH) Study Group. Clin Cardiol 2000;23:341-6.
16. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-21.
17. Goff DC Jr, Gu L, Cantley LK, Parker DG, Cohen SJ. Enhancing the quality of care for patients with coronary heart disease: the design and baseline results of the Hastening the Effective Application of Research through Technology (HEART) trial. Am J Managed Care 2002 (in press).
18. National Center for Health Statistics. The international classification of diseases, 9th revision, clinical modification. Ann Arbor, Mich: Edwards Brothers; 1978.
19. American Medical Association. Current procedural terminology: CPT. Chicago: American Medical Association; 1998.
20. Fishbein M. A theory of reasoned action: some applications and implications. Nebr Symp Motiv 1980;27:65-116.
21. Bandura A. Social foundation of thought and action: a social-cognitive theory. Englewood Cliffs, NJ: Prentice-Hall; 1986.
22. Rogers EM. Diffusion of innovations. New York: Free Press; 1983.
23. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44: 1049-60. [Published erratum appears in Biometrics 1989;45: 347.]
24. Preisser JS, Young ML, Zaccaro DJ, Wolfson M. An integrated population-averaged approach to the design, analysis and sample size determination of cluster-unit trials. Stat Med 2003;22:1235-54.
25. Landry MD, Sibbald WJ. Changing physician behavior: a review of patient safety in critical care medicine. J Crit Care 2002;17: 138-45.
26. Baskerville NB, Hogg W, Lemelin J. Process evaluation of a tailored multifaceted approach to changing family physician practice patterns improving preventive care. J Fam Pract 2001;50: W242-9.
27. Davis DA, Taylor-Vaisey A. Translating guidelines into practice: a systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997;157:408-16.
28. McPhee SJ, Bird JA. Implementation of cancer prevention guidelines in clinical practice. J Gen Intern Med 1990;5(Suppl):S116-22.
29. Barton MB, Schoenbaum SC. Improving influenza vaccination performance in an HMO setting: the use of computer-generated reminders and peer comparison feedback. Am J Public Health 1990;80:534-6.
30. Cohen SJ. Efficacy, effectiveness, and sustainability: translating research into improvements in health care. Med Care 2000;38: 449-50.
31. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
32. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
33. Anonymous. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
34. Goff DC Jr, Cantley LK, Gu L. Increasing the appropriate use of reductase inhibitors among patients with coronary heart disease enrolled in a network-model managed care organization. Prev Managed Care 2000;1:141-8.
35. Rich SE, Shah J, Rich DS, Shah R, Rich MW. Effects of age, sex, race, diagnosis-related group, and hospital setting on lipid management in patients with coronary artery disease. Am J Cardiol 2000;86:328-30.